Phase III trials EMN441 (NCT01091831) and EMN01 (NCT01093196) both investigated progression-free survival (PFS), overall survival (OS) and time to next treatment, in newly diagnosed multiple myeloma (MM) patients given maintenance therapy of either lenalidomide and prednisone (RP), or lenalidomide alone (R). Francesca Gay, MD, from the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy, spoke about the results from a meta-analysis of these trials at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This analysis showed that despite a trend towards improved PFS for RP therapy, overall PFS, OS, and time to next treatment were not statistically different between treatments, suggesting R therapy should continue as the standard maintenance.
Lenalidomide maintenance remains best for newly diagnosed MM
